通策醫療(600763.SH)跳水一度逼近跌停
格隆匯1月6日丨通策醫療上午10點左右突然跳水,盤中一度跌逼近跌停(跌9.1%至174.22元),半日收跌5.94%報180.19元,股價創2020年8月以來新低,最新市值578億元。通策醫療2021年累計收跌28%,目前市盈率仍高達80倍。近日,有投資者在互動平台上提問通策醫療稱,2021第四季度疫情嚴重,貴公司有多少個園區停擺?2022第一季度疫情也不容樂觀,對公司的經營產生了重大不利影響,業績是否大幅下滑? 全年業績是否同比增長為個位數?對此,董祕迴應稱,目前公司體系內除北侖分院按當地防疫要求短暫停診外,目前其他各主要醫院均處於正常營業狀態,具體業績數據請期待公司將披露的定期報吿。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.